Research graph
References from Precision medicine in cancer: A comprehensive review of advanced cancer diagnosis technologies and personalized treatment strategies. Local targets link to admitted publications; unresolved targets remain external evidence.
Precision medicine—personalized, problematic, and promising
10.1097/01.ogx.0000472121.21647.38 · 2015 · External reference
Precision oncology: an overview
10.1200/jco.2013.49.4799 · 2013 · External reference
The evolving landscape of tissue‐agnostic therapies in precision oncology
2024 · External reference
Developing drugs for tissue‐agnostic indications: a paradigm shift in leveraging cancer biology for precision medicine
10.1002/cpt.1946 · 2021 · External reference
Advances in tissue‐agnostic targeting in cancer therapeutics: current approvals, challenges, and future directions
10.32604/or.2025.067791 · 2025 · External reference
The hallmarks of tissue‐agnostic therapies and strategies for early anticancer drug discovery
10.1016/j.drudis.2024.104203 · 2024 · External reference
Tissue‐agnostic cancer therapy approvals
10.1016/j.soc.2023.12.001 · 2024 · External reference
From tissue‐agnostic to N‐of‐one therapies:(R) evolution of the precision paradigm
10.1016/j.trecan.2020.08.009 · 2021 · External reference
Rethinking cancer drug development through tumor‐agnostic precision medicine
10.1158/2159-8290.cd-25-1457 · 2025 · External reference
Clinical implications of intratumor heterogeneity: challenges and opportunities
10.1007/s00109-020-01874-2 · 2020 · External reference
Tumor heterogeneity: development, mechanisms, and therapeutic implications
10.1038/s41392-026-02749-7 · 2026 · External reference
Intratumoral heterogeneity, its contribution to therapy resistance and methodological caveats to assessment
10.3389/fonc.2014.00142 · 2014 · External reference
Heterogeneity in precision oncology
10.1017/pcm.2023.23 · 2024 · External reference
Cancer cell cycle heterogeneity as a critical determinant of therapeutic resistance
10.1016/j.gendis.2022.11.025 · 2024 · External reference
Comprehensive multi‐omics analysis provides biological insights and therapeutic strategies for small‐cell lung cancer
10.1002/mco2.569 · 2024 · External reference
Integrative multi‐omics approaches in cancer research: from biological networks to clinical subtypes
10.14348/molcells.2021.0042 · 2021 · External reference
Liquid biopsy and multi‐omic biomarkers in breast cancer: innovations in early detection, therapy guidance, and disease monitoring
2025 · External reference
Multi‐omics analysis: paving the path toward achieving precision medicine in cancer treatment and immuno‐oncology
10.3389/fmolb.2022.962743 · 2022 · External reference
Unresolved reference
2025 · External reference
Unresolved reference
External reference
Progress in research on tumor microenvironment‐based spatial omics technologies
10.32604/or.2023.029494 · 2023 · External reference
Artificial intelligence meets epigenetics: a new frontier in precision oncology
10.1080/28361512.2026.2614541 · 2026 · External reference
Genomics and the history of precision oncology
10.1016/j.soc.2019.08.003 · 2019 · External reference
Advances in precision oncology: from molecular profiling to regulatory‐approved targeted therapies
10.3390/cancers17213500 · 2025 · External reference
Integrated and comprehensive diagnostics: an emerging paradigm in precision oncology
10.3390/cancers18020327 · 2026 · External reference
New clinical trial designs in the era of precision medicine: an overview of definitions, strengths, weaknesses, and current use in oncology
10.1016/j.ctrv.2018.12.003 · 2019 · External reference
Deep learning: new computational modelling techniques for genomics
10.1038/s41576-019-0122-6 · 2019 · External reference
Advancing precision oncology with AI‐powered genomic analysis
10.3389/fphar.2025.1591696 · 2025 · External reference
Artificial intelligence in cancer research, diagnosis and therapy
10.1038/s41568-021-00399-1 · 2021 · External reference
Artificial intelligence in variant calling: a review
10.3389/fbinf.2025.1574359 · 2025 · External reference
Deep learning‐based prediction of tumor mutational burden from digital pathology slides: a comprehensive review
10.3390/app16031340 · 2026 · External reference
Deep learning can predict microsatellite instability directly from histology in gastrointestinal cancer
10.1038/s41591-019-0462-y · 2019 · External reference
HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures
10.1038/nm.4292 · 2017 · External reference
Explainable AI model reveals informative mutational signatures for cancer‐type classification
10.3390/cancers17111731 · 2025 · External reference
Disease variant prediction with deep generative models of evolutionary data
10.1038/s41586-021-04043-8 · 2021 · External reference
Tumor‐agnostic therapies in practice: challenges, innovations, and future perspectives
10.3390/cancers17050801 · 2025 · External reference
Harnessing tumor‐agnostic biomarkers for precision medicine in lymphoma
2026 · External reference
Antibody‐drug conjugates in precision oncology
10.1016/j.ccell.2026.05.004 · 2026 · External reference
Antibody‐drug conjugates in solid tumor oncology and the frontier of precision immunosuppression: a mechanistic, translational, and clinical review
10.3390/ijms27125196 · 2026 · External reference
Antibody–drug conjugates in cancer therapy: current landscape, challenges, and future directions
10.1186/s12943-025-02489-2 · 2025 · External reference
Innovative payloads for ADCs in cancer treatment: moving beyond the selective delivery of chemotherapy
10.1177/17588359241309461 · 2025 · External reference
Advances in the delivery of anticancer drugs by nanoparticles and chitosan‐based nanoparticles
2024 · External reference
AI‐powered mapping of tumor immunity for optimized mRNA vaccine engineering
10.3389/fonc.2026.1766201 · 2026 · External reference
Prediction of lipid nanoparticles for mRNA vaccines by the machine learning algorithm
10.1016/j.apsb.2021.11.021 · 2022 · External reference
Key clinical frontiers of mRNA loaded lipid nanoparticles in cancer vaccines
10.2147/ijn.s565558 · 2025 · External reference
Artificial intelligence‐driven strategies for targeted delivery and enhanced stability of RNA‐based lipid nanoparticle cancer vaccines
10.3390/pharmaceutics17080992 · 2025 · External reference
Advances in personalized cancer vaccine development: AI applications from neoantigen discovery to mRNA formulation
10.3390/biochem5020005 · 2025 · External reference
Personalized cancer vaccine design using AI‐powered technologies
10.3389/fimmu.2024.1357217 · 2024 · External reference
Neoantigen‐driven cancer vaccines in personalized oncology: progress, obstacles, and translational prospects
10.1007/s11033-025-11421-2 · 2026 · External reference
Drug resistance in cancer: molecular mechanisms and emerging treatment strategies
10.1186/s43556-025-00352-w · 2025 · External reference
Current landscape of therapeutic resistance in lung cancer and promising strategies to overcome resistance
10.3390/cancers14194562 · 2022 · External reference
10.1002/9781394376490.ch3
10.1002/9781394376490.ch3 · 2026 · External reference
Challenges and opportunities for precision medicine in developing nations
10.1080/23808993.2025.2505796 · 2025 · External reference
Socioeconomic disparities in health‐related quality of life and healthcare use in the last year of life of patients with advanced cancer: longitudinal results from the eQuiPe study
2025 · External reference
Socioeconomic disparities in healthcare access and implications for all‐cause mortality among US adults: a 2000‐2019 record linkage study
10.1093/aje/kwae202 · 2025 · External reference
Onco‐multi‐OMICS approach: a new frontier in cancer research
2018 · External reference
LinkedOmics: analyzing multi‐omics data within and across 32 cancer types
10.1093/nar/gkx1090 · 2018 · External reference
Next‐generation sequencing: a review of its transformative impact on cancer diagnosis, treatment, and resistance management
10.3390/diagnostics15192425 · 2025 · External reference
Next‐generation sequencing (NGS) technologies: transformative impact on genomics and personalized medicine
10.56557/jirmeps/2026/v21i110088 · 2026 · External reference
NGS approaches in clinical diagnostics: from workflow to disease‐specific applications
10.3390/ijms26199597 · 2025 · External reference
Tumor mutational burden as a predictive biomarker in solid tumors
10.1158/2159-8290.cd-20-0522 · 2020 · External reference
Microsatellite instability: a review of molecular epidemiology and implications for immune checkpoint inhibitor therapy
10.3390/cancers15082288 · 2023 · External reference
The homologous recombination deficiency scar in advanced cancer: agnostic targeting of damaged DNA repair
10.3390/cancers14122950 · 2022 · External reference
Multi‐OMICS approaches in cancer biology: new era in cancer therapy
2024 · External reference
Advances in epigenomic sequencing and their applications in cancer diagnostics
10.1021/prechem.5c00014 · 2025 · External reference
RNA‐Seq: a revolutionary tool for transcriptomics
10.1038/nrg2484 · 2009 · External reference
Unresolved reference
External reference
Proteomic analysis of protein posttranslational modifications by mass spectrometry
10.1101/pdb.top077743 · 2016 · External reference
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
10.1186/s12943-023-01827-6 · 2023 · External reference
Quantitative analysis of IGF1R/AKT/mTOR pathway using multiplex immunoprecipitation and targeted mass spectrometry
10.1158/1538-7445.am2016-3884 · 2016 · External reference
Advances in microfluidic systems and numerical modeling in biomedical applications: a review
10.3390/mi15070873 · 2024 · External reference
The technological landscape and applications of single‐cell multi‐omics
10.1038/s41580-023-00615-w · 2023 · External reference
Microfluidic single‐cell transcriptomics: moving towards multimodal and spatiotemporal omics
10.1039/d1lc00607j · 2021 · External reference
From morphology to single‐cell molecules: high‐resolution 3D histology in biomedicine
10.1186/s12943-025-02240-x · 2025 · External reference
Spatial omics in clinical research: a comprehensive review of technologies and guidelines for applications
10.3390/ijms26093949 · 2025 · External reference
Cancer‐associated fibroblasts in the tumor microenvironment: heterogeneity, crosstalk mechanisms, and therapeutic implications
10.1186/s12943-025-02533-1 · 2025 · External reference
Significance and limitations of the use of next‐generation sequencing technologies for detecting mutational signatures
10.1016/j.dnarep.2021.103200 · 2021 · External reference
Advancements and applications of single‐cell multi‐omics techniques in cancer research: unveiling heterogeneity and paving the way for precision therapeutics
2024 · External reference
Single‐cell multiomics
10.1146/annurev-biodatasci-020422-050645 · 2023 · External reference
Spatial transcriptomics, proteomics, and epigenomics as tools in tissue engineering and regenerative medicine
10.3390/bioengineering11121235 · 2024 · External reference
The good, the bad, and the ugly: opportunities, challenges, and pitfalls in spatial proteomics modeling
10.1093/bib/bbag169 · 2026 · External reference
A review of circulating tumor DNA (ctDNA) and the liquid biopsy in cancer diagnosis, screening, and monitoring treatment response
10.12659/msm.949300 · 2025 · External reference
Patient‐derived tumor organoids: a new avenue for preclinical research and precision medicine in oncology
10.1038/s12276-024-01272-5 · 2024 · External reference
Oncogenic driver mutations, treatment, and EGFR‐TKI resistance in a Caucasian population with non‐small cell lung cancer: survival in clinical practice
10.18632/oncotarget.20857 · 2017 · External reference
Tissue‐agnostic cancer therapies: promise, reality, and the path forward
10.1038/s41467-025-60369-1 · 2025 · External reference
Trop2‐targeted therapies in solid tumors: advances and future directions
10.7150/thno.98178 · 2024 · External reference
Sacituzumab govitecan and trastuzumab deruxtecan: two new antibody–drug conjugates in the breast cancer treatment landscape
10.1016/j.esmoop.2021.100204 · 2021 · External reference
Tumor type agnostic therapy carrying BRAF mutation: case reports and review of literature
10.3390/ph14020159 · 2021 · External reference
Clinical evidence for efficacy of pembrolizumab in MSI‐H and TMB‐H advanced solid tumor: results from three cancer centers in China
10.1007/s00262-024-03660-2 · 2024 · External reference
The evolving landscape of antibody–drug conjugates: in depth analysis of recent research progress
10.1021/acs.bioconjchem.3c00374 · 2023 · External reference
Bystander effect in antibody‐drug conjugates: navigating the fine line in tumor heterogeneity
10.1016/j.critrevonc.2025.104979 · 2025 · External reference
Antibody drug conjugates in breast cancer: spotlight on HER2
10.1097/ppo.0000000000000634 · 2022 · External reference
Recent advances in mRNA cancer vaccines: meeting challenges and embracing opportunities
10.3389/fimmu.2023.1246682 · 2023 · External reference
Personalized cancer vaccines: bridging immune‐oncology and precision medicine for advanced therapeutics
10.1038/s41392-026-02769-3 · 2026 · External reference
Liquid biopsy in cancer drug resistance: real‐time monitoring, mechanistic insights, and translational applications
10.3389/fimmu.2026.1795789 · 2026 · External reference
Integrating cfDNA liquid biopsy and organoid‐based drug screening reveals PI3K signaling as a promising therapeutic target in colorectal cancer
10.1186/s12967-023-04675-6 · 2024 · External reference
Liquid biopsy: an evolving paradigm for non‐invasive disease diagnosis and monitoring in medicine
2023 · External reference
Liquid biopsy to detect minimal residual disease: methodology and impact
10.3390/cancers13215364 · 2021 · External reference
Liquid biopsy approaches for cancer characterization, residual disease detection, and therapy monitoring
10.1200/edbk-25-481114 · 2025 · External reference
Applications of organoids for cancer biology and precision medicine
10.1038/s43018-020-0102-y · 2020 · External reference
PTOLEMI: personalized cancer treatment through machine learning‐enabled image analysis of microfluidic assays
10.3390/diagnostics13193075 · 2023 · External reference
AI‐driven multi‐omics integration in precision oncology: bridging the data deluge to clinical decisions
10.1007/s10238-025-01965-9 · 2025 · External reference
Artificial intelligence in multidisciplinary tumor boards enhancing decision making and clinical outcomes in oncology
10.1016/j.isci.2025.114082 · 2025 · External reference
Challenges and solutions to system‐wide use of precision oncology as the standard of care paradigm
10.1017/pcm.2024.1 · 2024 · External reference
Addressing the challenges of applying precision oncology
10.1038/s41698-017-0032-z · 2017 · External reference
10.1002/9781394376490.ch3
10.1002/9781394376490.ch3 · ExternalCitation · doi-reference
Developing drugs for tissue‐agnostic indications: a paradigm shift in leveraging cancer biology for precision medicine
10.1002/cpt.1946 · ExternalCitation · doi-reference
Comprehensive multi‐omics analysis provides biological insights and therapeutic strategies for small‐cell lung cancer
10.1002/mco2.569 · ExternalCitation · doi-reference
Clinical implications of intratumor heterogeneity: challenges and opportunities
10.1007/s00109-020-01874-2 · ExternalCitation · doi-reference
Clinical evidence for efficacy of pembrolizumab in MSI‐H and TMB‐H advanced solid tumor: results from three cancer centers in China
10.1007/s00262-024-03660-2 · ExternalCitation · doi-reference
AI‐driven multi‐omics integration in precision oncology: bridging the data deluge to clinical decisions
10.1007/s10238-025-01965-9 · ExternalCitation · doi-reference
Neoantigen‐driven cancer vaccines in personalized oncology: progress, obstacles, and translational prospects
10.1007/s11033-025-11421-2 · ExternalCitation · doi-reference
Prediction of lipid nanoparticles for mRNA vaccines by the machine learning algorithm
10.1016/j.apsb.2021.11.021 · ExternalCitation · doi-reference
Antibody‐drug conjugates in precision oncology
10.1016/j.ccell.2026.05.004 · ExternalCitation · doi-reference
Bystander effect in antibody‐drug conjugates: navigating the fine line in tumor heterogeneity
10.1016/j.critrevonc.2025.104979 · ExternalCitation · doi-reference
New clinical trial designs in the era of precision medicine: an overview of definitions, strengths, weaknesses, and current use in oncology
10.1016/j.ctrv.2018.12.003 · ExternalCitation · doi-reference
Significance and limitations of the use of next‐generation sequencing technologies for detecting mutational signatures
10.1016/j.dnarep.2021.103200 · ExternalCitation · doi-reference
The hallmarks of tissue‐agnostic therapies and strategies for early anticancer drug discovery
10.1016/j.drudis.2024.104203 · ExternalCitation · doi-reference
Sacituzumab govitecan and trastuzumab deruxtecan: two new antibody–drug conjugates in the breast cancer treatment landscape
10.1016/j.esmoop.2021.100204 · ExternalCitation · doi-reference
Cancer cell cycle heterogeneity as a critical determinant of therapeutic resistance
10.1016/j.gendis.2022.11.025 · ExternalCitation · doi-reference
Artificial intelligence in multidisciplinary tumor boards enhancing decision making and clinical outcomes in oncology
10.1016/j.isci.2025.114082 · ExternalCitation · doi-reference
Genomics and the history of precision oncology
10.1016/j.soc.2019.08.003 · ExternalCitation · doi-reference
Tissue‐agnostic cancer therapy approvals
10.1016/j.soc.2023.12.001 · ExternalCitation · doi-reference
From tissue‐agnostic to N‐of‐one therapies:(R) evolution of the precision paradigm
10.1016/j.trecan.2020.08.009 · ExternalCitation · doi-reference
Heterogeneity in precision oncology
10.1017/pcm.2023.23 · ExternalCitation · doi-reference
Challenges and solutions to system‐wide use of precision oncology as the standard of care paradigm
10.1017/pcm.2024.1 · ExternalCitation · doi-reference
The evolving landscape of antibody–drug conjugates: in depth analysis of recent research progress
10.1021/acs.bioconjchem.3c00374 · ExternalCitation · doi-reference
Advances in epigenomic sequencing and their applications in cancer diagnostics
10.1021/prechem.5c00014 · ExternalCitation · doi-reference
HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures
10.1038/nm.4292 · ExternalCitation · doi-reference
RNA‐Seq: a revolutionary tool for transcriptomics
10.1038/nrg2484 · ExternalCitation · doi-reference
Patient‐derived tumor organoids: a new avenue for preclinical research and precision medicine in oncology
10.1038/s12276-024-01272-5 · ExternalCitation · doi-reference
Tumor heterogeneity: development, mechanisms, and therapeutic implications
10.1038/s41392-026-02749-7 · ExternalCitation · doi-reference
Personalized cancer vaccines: bridging immune‐oncology and precision medicine for advanced therapeutics
10.1038/s41392-026-02769-3 · ExternalCitation · doi-reference
Tissue‐agnostic cancer therapies: promise, reality, and the path forward
10.1038/s41467-025-60369-1 · ExternalCitation · doi-reference
Artificial intelligence in cancer research, diagnosis and therapy
10.1038/s41568-021-00399-1 · ExternalCitation · doi-reference
Deep learning: new computational modelling techniques for genomics
10.1038/s41576-019-0122-6 · ExternalCitation · doi-reference
The technological landscape and applications of single‐cell multi‐omics
10.1038/s41580-023-00615-w · ExternalCitation · doi-reference
Disease variant prediction with deep generative models of evolutionary data
10.1038/s41586-021-04043-8 · ExternalCitation · doi-reference
Deep learning can predict microsatellite instability directly from histology in gastrointestinal cancer
10.1038/s41591-019-0462-y · ExternalCitation · doi-reference
Addressing the challenges of applying precision oncology
10.1038/s41698-017-0032-z · ExternalCitation · doi-reference
Applications of organoids for cancer biology and precision medicine
10.1038/s43018-020-0102-y · ExternalCitation · doi-reference
Microfluidic single‐cell transcriptomics: moving towards multimodal and spatiotemporal omics
10.1039/d1lc00607j · ExternalCitation · doi-reference
Challenges and opportunities for precision medicine in developing nations
10.1080/23808993.2025.2505796 · ExternalCitation · doi-reference
Artificial intelligence meets epigenetics: a new frontier in precision oncology
10.1080/28361512.2026.2614541 · ExternalCitation · doi-reference
Socioeconomic disparities in healthcare access and implications for all‐cause mortality among US adults: a 2000‐2019 record linkage study
10.1093/aje/kwae202 · ExternalCitation · doi-reference
The good, the bad, and the ugly: opportunities, challenges, and pitfalls in spatial proteomics modeling
10.1093/bib/bbag169 · ExternalCitation · doi-reference
LinkedOmics: analyzing multi‐omics data within and across 32 cancer types
10.1093/nar/gkx1090 · ExternalCitation · doi-reference
Precision medicine—personalized, problematic, and promising
10.1097/01.ogx.0000472121.21647.38 · ExternalCitation · doi-reference
Antibody drug conjugates in breast cancer: spotlight on HER2
10.1097/ppo.0000000000000634 · ExternalCitation · doi-reference
Proteomic analysis of protein posttranslational modifications by mass spectrometry
10.1101/pdb.top077743 · ExternalCitation · doi-reference
Single‐cell multiomics
10.1146/annurev-biodatasci-020422-050645 · ExternalCitation · doi-reference
Quantitative analysis of IGF1R/AKT/mTOR pathway using multiplex immunoprecipitation and targeted mass spectrometry
10.1158/1538-7445.am2016-3884 · ExternalCitation · doi-reference
Tumor mutational burden as a predictive biomarker in solid tumors
10.1158/2159-8290.cd-20-0522 · ExternalCitation · doi-reference
Rethinking cancer drug development through tumor‐agnostic precision medicine
10.1158/2159-8290.cd-25-1457 · ExternalCitation · doi-reference
Innovative payloads for ADCs in cancer treatment: moving beyond the selective delivery of chemotherapy
10.1177/17588359241309461 · ExternalCitation · doi-reference
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
10.1186/s12943-023-01827-6 · ExternalCitation · doi-reference
From morphology to single‐cell molecules: high‐resolution 3D histology in biomedicine
10.1186/s12943-025-02240-x · ExternalCitation · doi-reference
Antibody–drug conjugates in cancer therapy: current landscape, challenges, and future directions
10.1186/s12943-025-02489-2 · ExternalCitation · doi-reference
Cancer‐associated fibroblasts in the tumor microenvironment: heterogeneity, crosstalk mechanisms, and therapeutic implications
10.1186/s12943-025-02533-1 · ExternalCitation · doi-reference
Integrating cfDNA liquid biopsy and organoid‐based drug screening reveals PI3K signaling as a promising therapeutic target in colorectal cancer
10.1186/s12967-023-04675-6 · ExternalCitation · doi-reference
Drug resistance in cancer: molecular mechanisms and emerging treatment strategies
10.1186/s43556-025-00352-w · ExternalCitation · doi-reference
Liquid biopsy approaches for cancer characterization, residual disease detection, and therapy monitoring
10.1200/edbk-25-481114 · ExternalCitation · doi-reference
Precision oncology: an overview
10.1200/jco.2013.49.4799 · ExternalCitation · doi-reference
A review of circulating tumor DNA (ctDNA) and the liquid biopsy in cancer diagnosis, screening, and monitoring treatment response
10.12659/msm.949300 · ExternalCitation · doi-reference
Integrative multi‐omics approaches in cancer research: from biological networks to clinical subtypes
10.14348/molcells.2021.0042 · ExternalCitation · doi-reference
Oncogenic driver mutations, treatment, and EGFR‐TKI resistance in a Caucasian population with non‐small cell lung cancer: survival in clinical practice
10.18632/oncotarget.20857 · ExternalCitation · doi-reference
Key clinical frontiers of mRNA loaded lipid nanoparticles in cancer vaccines
10.2147/ijn.s565558 · ExternalCitation · doi-reference
Progress in research on tumor microenvironment‐based spatial omics technologies
10.32604/or.2023.029494 · ExternalCitation · doi-reference
Advances in tissue‐agnostic targeting in cancer therapeutics: current approvals, challenges, and future directions
10.32604/or.2025.067791 · ExternalCitation · doi-reference
Artificial intelligence in variant calling: a review
10.3389/fbinf.2025.1574359 · ExternalCitation · doi-reference
Recent advances in mRNA cancer vaccines: meeting challenges and embracing opportunities
10.3389/fimmu.2023.1246682 · ExternalCitation · doi-reference
Personalized cancer vaccine design using AI‐powered technologies
10.3389/fimmu.2024.1357217 · ExternalCitation · doi-reference
Liquid biopsy in cancer drug resistance: real‐time monitoring, mechanistic insights, and translational applications
10.3389/fimmu.2026.1795789 · ExternalCitation · doi-reference
Multi‐omics analysis: paving the path toward achieving precision medicine in cancer treatment and immuno‐oncology
10.3389/fmolb.2022.962743 · ExternalCitation · doi-reference
Intratumoral heterogeneity, its contribution to therapy resistance and methodological caveats to assessment
10.3389/fonc.2014.00142 · ExternalCitation · doi-reference
AI‐powered mapping of tumor immunity for optimized mRNA vaccine engineering
10.3389/fonc.2026.1766201 · ExternalCitation · doi-reference
Advancing precision oncology with AI‐powered genomic analysis
10.3389/fphar.2025.1591696 · ExternalCitation · doi-reference
Deep learning‐based prediction of tumor mutational burden from digital pathology slides: a comprehensive review
10.3390/app16031340 · ExternalCitation · doi-reference
Advances in personalized cancer vaccine development: AI applications from neoantigen discovery to mRNA formulation
10.3390/biochem5020005 · ExternalCitation · doi-reference
Spatial transcriptomics, proteomics, and epigenomics as tools in tissue engineering and regenerative medicine
10.3390/bioengineering11121235 · ExternalCitation · doi-reference
Liquid biopsy to detect minimal residual disease: methodology and impact
10.3390/cancers13215364 · ExternalCitation · doi-reference
The homologous recombination deficiency scar in advanced cancer: agnostic targeting of damaged DNA repair
10.3390/cancers14122950 · ExternalCitation · doi-reference
Current landscape of therapeutic resistance in lung cancer and promising strategies to overcome resistance
10.3390/cancers14194562 · ExternalCitation · doi-reference
Microsatellite instability: a review of molecular epidemiology and implications for immune checkpoint inhibitor therapy
10.3390/cancers15082288 · ExternalCitation · doi-reference
Tumor‐agnostic therapies in practice: challenges, innovations, and future perspectives
10.3390/cancers17050801 · ExternalCitation · doi-reference
Explainable AI model reveals informative mutational signatures for cancer‐type classification
10.3390/cancers17111731 · ExternalCitation · doi-reference
Advances in precision oncology: from molecular profiling to regulatory‐approved targeted therapies
10.3390/cancers17213500 · ExternalCitation · doi-reference
Integrated and comprehensive diagnostics: an emerging paradigm in precision oncology
10.3390/cancers18020327 · ExternalCitation · doi-reference
PTOLEMI: personalized cancer treatment through machine learning‐enabled image analysis of microfluidic assays
10.3390/diagnostics13193075 · ExternalCitation · doi-reference
Next‐generation sequencing: a review of its transformative impact on cancer diagnosis, treatment, and resistance management
10.3390/diagnostics15192425 · ExternalCitation · doi-reference
Spatial omics in clinical research: a comprehensive review of technologies and guidelines for applications
10.3390/ijms26093949 · ExternalCitation · doi-reference
NGS approaches in clinical diagnostics: from workflow to disease‐specific applications
10.3390/ijms26199597 · ExternalCitation · doi-reference
Antibody‐drug conjugates in solid tumor oncology and the frontier of precision immunosuppression: a mechanistic, translational, and clinical review
10.3390/ijms27125196 · ExternalCitation · doi-reference
Advances in microfluidic systems and numerical modeling in biomedical applications: a review
10.3390/mi15070873 · ExternalCitation · doi-reference
Tumor type agnostic therapy carrying BRAF mutation: case reports and review of literature
10.3390/ph14020159 · ExternalCitation · doi-reference
Artificial intelligence‐driven strategies for targeted delivery and enhanced stability of RNA‐based lipid nanoparticle cancer vaccines
10.3390/pharmaceutics17080992 · ExternalCitation · doi-reference
Next‐generation sequencing (NGS) technologies: transformative impact on genomics and personalized medicine
10.56557/jirmeps/2026/v21i110088 · ExternalCitation · doi-reference
Trop2‐targeted therapies in solid tumors: advances and future directions
10.7150/thno.98178 · ExternalCitation · doi-reference
